Financial Services

A family-owned store's record safe sales reveal a story of niche retail, tax incentives, and a parent company's ambitious 'patriotic lifestyle' gamble.

A famed NYC pub's arrival signals a new era for Atlanta's downtown, as the massive Centennial Yards project races to redefine the city for a global stage.

A massive silver discovery in Nevada isn't just a win for one company; it's a strategic move to secure America's tech and energy future. Here's why.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

A top FinTech firm's new product chief reveals a strategic roadmap for taming complexity that the defense and space sectors cannot afford to ignore.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

As AI systems grow more powerful, they also become vulnerable. A new German research initiative aims to build the tools to detect AI manipulation.

Wealth Enhancement's $2.2B deal for L.M. Kohn isn't just another acquisition. It signals a tech-fueled consolidation wave reshaping financial advice.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Accenture is training 30,000 pros on Anthropic's Claude AI, tackling the biggest barrier to enterprise AI: moving from costly experiments to real value.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A quiet investment in a communication platform is making a loud statement about the future of work and education. Here’s why it matters for your brand.

A Chinese city is investing in a new tourism model, blending adrenaline sports and ancient culture to capture a lucrative youth market. A strategic play.

A new initiative empowers local leaders to deploy a data-backed 'catch-up' learning method, aiming to solve Africa's foundational education crisis.